^
Association details:
| Biomarker: | NOTCH1 mutation |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Imbruvica (ibrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Genomic Alterations and Outcomes With Fixed‑Duration Ibrutinib + Venetoclax: Results From the Phase 3 GLOW Study in Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Published date:
09/01/2023
Excerpt:
PFS was significantly improved with Ibr+Ven vs Clb+O across all genomic subgroups, and numerically favored in trisomy-12 (HR 0.58), NOTCH1mut (HR 0.42), and IGLL5mut (HR 0.15).
Trial ID:
